Sleep Disorder Clinical Trials in Columbia, SC
Sleep Clinical Trials
At Bogan Sleep Consultants, we are committed to helping you achieve the restful sleep you deserve. We are thrilled to invite you to explore the possibility of participating in our clinical trials, where you can contribute to the advancement of sleep medicine.
What is a Clinical Trial?
A clinical trial is a research study designed to evaluate new treatments and therapies. These trials provide critical insights that help improve existing treatments and develop innovative solutions for various sleep disorders. By participating in a clinical trial, you become an essential part of the journey to enhance the quality of sleep care for everyone.
Why Participate in a Sleep Clinical Trial?
Participating in a clinical trial offers numerous benefits:
- Access to Cutting-Edge Treatments: Be among the first to experience new therapies that are not yet widely available.
- Expert Care and Monitoring: Receive care from our highly qualified team of sleep specialists who are leaders in the field of sleep medicine.
- Contribute to Medical Research: Your involvement helps pave the way for future advancements in sleep medicine, potentially benefiting thousands of others.
- Personalized Attention: As a participant, you receive individualized care and attention from Dr. Bogan and Dr. Herpel throughout the study.
If you are interested in seeing if you qualify for one of our clinical trials, we encourage you to contact us. Our team is here to provide all the necessary information and support to guide you through the process. Together, we can work toward better sleep and better health for everyone.
Our Current Sleep Studies
Narcolepsy Studies
- Jazz (JZP258-406): An open-label, multicenter switch study evaluating changes in blood pressure in participants. Switching from high-sodium oxybate to Xywav.
You may be eligible for this study if you have a diagnosis of narcolepsy. The study will require about 8 visits over 11 weeks. - Alkermes (ALKS2680-201)- A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1.
You may be eligible if you have been diagnosed with Narcolepsy Type 1, are between the ages of 18 and 70, and have a BMI > 18 and < 35 kh/m2. You may be asked to stop taking any medications prescribed for the management of narcolepsy symptoms, including excessive daytime sleepiness. - Alkermes (ALKS2680-202)- A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2.
You may be eligible if you have been diagnosed with Narcolepsy Type 2, are between the ages of 18 and 70, and have a BMI > 18 and < 35 kh/m2. You may be asked to stop taking any medications prescribed for the management of narcolepsy symptoms, including excessive daytime sleepiness. - Takeda (TAK861-3001)- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1).
You may be eligible if you have been diagnosed with Narcolepsy Type 1, are between the ages of 18 and 70, and have a BMI within the range of 18 to 40kg/m2. You may be asked to stop taking any medications prescribed for the management of Narcolepsy symptoms, including excessive daytime sleepiness. - Eisai (E2086-A001-101)- A Randomized, Double-Blind, Single-Dose, 5-Period Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Modafinil in Adult Subjects with Narcolepsy Type 1.
You may be eligible if you have been diagnosed with Narcolepsy Type 1, are older than 18, and have a BMI between ≥18 to <40 kg/m2. You may be asked to stop taking any medications prescribed for the management of Narcolepsy symptoms, including excessive daytime sleepiness. - Takeda (TAK-360-2001)- A Dose-Finding, Adaptive Trial with Randomized, Double-Blinded, Placebo-Controlled Period, followed by an Active Only Extension Period to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Narcolepsy without Cataplexy (NT2)
Potential subject must be between the ages of 18 to 70 years, inclusive, at the time of informed consent. The body mass index (BMI) must be between 18kg/m2 to 40kg/m2. You may be asked to stop any current medications that you are taking for Narcolepsy. - Centessa (ORX750-0201)- A Phase 2a, Randomized, Double-blind, Sponsor-open, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ORX750 in Subjects with Narcolepsy and Idiopathic Hypersomnia.
Potential subjects must be ages 18 to 65 years, inclusive, at the time of informed consent. Body mass index (BMI) must be less than 40kg/m2. You may be asked to stop any current medications that you are taking for Narcolepsy.
Obstructive Sleep Apnea Studies
- Nyxoah (CL-CCC2022)- A Multicenter study to assess the safety and effectiveness of the Genro Dual Sided Hypoglossal nerve stimulation system for the treatment of obstructive sleep apnea in subjects with complete concentric collapse of the soft palate.
You may be eligible for this study if you are between ages 22-75, your BMI is less than 32kg/m2, and you have failed PAP therapy. - Breas (BMCI-002) – Prospective, multicenter, single-blind, randomized, crossover study evaluating the safety and effectiveness of auto-EPAP feature versus manual EPAP in the Vivo 45 LS Ventilator.
- 18 years old or older
- Currently using non-invasive ventilation (NIV) to treat chronic hypercapnic respiratory insufficiency or respiratory failure due to:
- Chronic Obstructive Pulmonary Disease (COPD)
- Obesity Hypoventilation Syndrome (OHS)
- Neuromuscular Disease (NMD)
- Other Hypercapnic diagnosis
- Have co-existing obstructive sleep apnea (OSA)
Insomnia Study
- Idorsia (ID-078A205)- Multi-center, double-blind, randomized, placebo-controlled, parallel-group, polysomnography, dose-finding study assessing the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to < 18 years with insomnia disorder.
Your child may be eligible for this study if they are between ages 10-18 and weigh more than 55lbs.
Shift Work Disorder Study
- Axsome (SOL-SWD-301)- A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Solriamfetol in Excessive Sleepiness Associated with Shift Work Disorder.
You may be eligible if you are between the ages of 18 and 65, have a BMI between 18 and 45kg/m2, and work at least 5 night shifts per month with at least 3 of the night shifts occurring in consecutive nights.
Idiopathic Hypersomnia Study
- Avadel (CLFT218-2401)- A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of FT218 in the Treatment of Idiopathic Hypersomnia (IH).
You may be eligible if you have been diagnosed with IH and are between the ages of 18 and 75. - Takeda (TAK-360-2002)- A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH)
- Centessa (ORX750-0201)- A Phase 2a, Randomized, Double-blind, Sponsor-open, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ORX750 in Subjects with Narcolepsy and Idiopathic Hypersomnia
Potential subjects must be ages 18 to 65 years, inclusive, at the time of informed consent. Body mass index must be less than 40kg/m2. You may be asked to stop any current medications that you are taking for Idiopathic Hypersomnia.
Feel free to reach out to us today to learn more about our clinical trials and how you can be a part of this exciting opportunity. We look forward to welcoming you to the Bogan Sleep family.